By Gina Shaw
The Centers for Medicare & Medicaid Services (CMS) has announced a preliminary National Coverage Determination (NCD) restricting Medicare coverage of the Alzheimer’s disease (AD) drug aducanumab-avwa (Aduhelm, Biogen) to patients who are participating in approved placebo-controlled clinical trials. The final NCD is expected to be issued by April 11, after a public comment period.
JANUARY 12, 2022